CP
FENC icon

CenterBook Partners’s Fennec Pharmaceuticals FENC Stock Holding History

CenterBook Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
+118,582
New +$968K 0.06% 317

Other funds holding FENC

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

CenterBook Partners's FENC Position: Q2 2026 in Review

CenterBook Partners opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 118,582 shares worth $1.27M. The stake represents 0.06% of the portfolio and ranks #317 among its holdings.

50 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • CenterBook Partners held 118,582 shares of Fennec Pharmaceuticals worth $1.27M as of Q2 2026.
  • Fennec Pharmaceuticals was a new CenterBook Partners position in Q2 2026.
  • Fennec Pharmaceuticals made up 0.06% of CenterBook Partners's portfolio in Q2 2026, its #317 holding.
  • 50 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.